[go: up one dir, main page]

CL2016000183A1 - Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación - Google Patents

Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Info

Publication number
CL2016000183A1
CL2016000183A1 CL2016000183A CL2016000183A CL2016000183A1 CL 2016000183 A1 CL2016000183 A1 CL 2016000183A1 CL 2016000183 A CL2016000183 A CL 2016000183A CL 2016000183 A CL2016000183 A CL 2016000183A CL 2016000183 A1 CL2016000183 A1 CL 2016000183A1
Authority
CL
Chile
Prior art keywords
granules
pharmaceutical composition
tablet
rifapentin
redispersible
Prior art date
Application number
CL2016000183A
Other languages
English (en)
Inventor
Prassad Kum
Khullar Praveen
Prajapati Dilip
Kumar Ramesh
Kumar Shakti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000183A1 publication Critical patent/CL2016000183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICION FARMACEUTICA ORAL DE DOSIS FIJA EN FORMA DE UN COMPRIMIDO DISPERSABLE PARA TRATAR TUBERCULOSIS QUE COMPRENDE: A) GRANULOS QUE COMPRENDEN ISONIAZID Y UN EXCIPIENTE INTRAGRANULAR, B) GRANULOS QUE COMPRENDEN RIFAPENTINA Y UN EXCIPIENTE INTRAGRANULAR Y C) AL MENOS UN EXCIPIENTE INTRAGRANULAR; Y PROCESO PARA PREPARARLA.
CL2016000183A 2013-07-26 2016-01-22 Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación CL2016000183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3342CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
CL2016000183A1 true CL2016000183A1 (es) 2016-07-01

Family

ID=51211798

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000183A CL2016000183A1 (es) 2013-07-26 2016-01-22 Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Country Status (18)

Country Link
US (1) US9814680B2 (es)
EP (1) EP3024444A1 (es)
JP (2) JP2016539110A (es)
CN (1) CN105407876B (es)
AU (1) AU2014295099B2 (es)
CA (1) CA2918528A1 (es)
CL (1) CL2016000183A1 (es)
HK (1) HK1218861A1 (es)
IL (1) IL243369A0 (es)
MX (1) MX2016001155A (es)
PE (1) PE20160245A1 (es)
PH (1) PH12016500119A1 (es)
RU (1) RU2694056C2 (es)
SA (1) SA516370446B1 (es)
SG (2) SG11201510732VA (es)
TW (1) TWI630911B (es)
WO (1) WO2015011162A1 (es)
ZA (1) ZA201600110B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001156A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion.
EP4240392A4 (en) * 2020-11-09 2024-10-09 Realta Life Sciences, Inc. PEPTIDE FORMULATIONS AND METHODS OF USE
CN112730657A (zh) * 2020-12-18 2021-04-30 卓和药业集团有限公司 利福喷丁含量的分析检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
NZ518216A (en) * 2000-08-09 2004-11-26 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
AU2001294250A1 (en) * 2000-10-16 2002-04-29 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions quickly disintegrating in the oral cavity and process forproducing the same
BR0116994A (pt) 2001-04-27 2004-03-02 Lupin Ltd Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
TW201434467A (zh) 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
WO2011012987A1 (en) 2009-07-31 2011-02-03 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of isoniazid
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2012013756A2 (fr) 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
MX2016001156A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion.
SG11201510730UA (en) 2013-07-26 2016-01-28 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Also Published As

Publication number Publication date
JP2016539110A (ja) 2016-12-15
AU2014295099B2 (en) 2019-07-11
RU2016106328A (ru) 2017-08-31
JP6476331B2 (ja) 2019-02-27
EP3024444A1 (en) 2016-06-01
PH12016500119A1 (en) 2016-04-25
CN105407876B (zh) 2019-08-30
TW201601723A (zh) 2016-01-16
WO2015011162A1 (en) 2015-01-29
US9814680B2 (en) 2017-11-14
ZA201600110B (en) 2017-04-26
MX2016001155A (es) 2016-04-29
IL243369A0 (en) 2016-02-29
HK1218861A1 (zh) 2017-03-17
RU2694056C2 (ru) 2019-07-09
SG11201510732VA (en) 2016-01-28
PE20160245A1 (es) 2016-05-10
JP2018123147A (ja) 2018-08-09
CA2918528A1 (en) 2015-01-29
AU2014295099A1 (en) 2016-02-11
SG10201803996WA (en) 2018-06-28
CN105407876A (zh) 2016-03-16
SA516370446B1 (ar) 2018-09-13
TWI630911B (zh) 2018-08-01
US20160184231A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2015002148A1 (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
CR20170604A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
AR110374A1 (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
IN2013MU02110A (es)
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
IN2013MU02111A (es)